NCT02660008 Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon Status COMPLETED Phase PHASE2
NCT02656069 Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics Status COMPLETED Phase PHASE3
NCT02550145 Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery Status TERMINATED Phase PHASE1
NCT02459938 Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia Status COMPLETED Phase PHASE1
NCT02424500 Multi-Center Study Comparing Efficacy and Safety of Frequently Modified Insulin Therapy Status COMPLETED Phase NA
NCT02403648 Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons Status COMPLETED Phase PHASE1
NCT02402933 Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents Status COMPLETED Phase PHASE3
NCT02390141 Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207 Status COMPLETED Phase PHASE1
NCT02380339 A Combined Biofeedback-virtual Reality System for Reduction of Fear of Hypoglycemia Status UNKNOWN Phase NA
NCT02367053 Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator Status COMPLETED Phase PHASE1